Memorial Sloan Kettering Cancer Center: Carcinoma, Renal Cell trials

The registry lists 26 Carcinoma, Renal Cell studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 4 are open to participants now and 6 have results posted.

Phase 1 9Phase 2 18Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Treatment Delivery Preference In People With Kidney CancerRecruitingNCT07872553Phase 4
• A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingNCT06835972Phase 1/2
• A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell CarcinomaRecruitingNCT06699602Phase 2
• A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft TissueRecruitingNCT05837767Not applicable
• Talazoparib and Axitinib for People With Previously Treated Advanced Kidney CancerCompletedNCT04337970Phase 1/2Results posted
• Talazoparib and Avelumab in Participants With Metastatic Renal Cell CarcinomaCompletedNCT04068831Phase 2Results posted
• BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)TerminatedNCT01453595Phase 1/2Results posted
• Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)CompletedNCT01399918Phase 2Results posted
• Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or MelanomaCompletedNCT00462982Phase 2Results posted
• Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney CancerCompletedNCT00459875Phase 2Results posted
• A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the BrainActive, not recruitingNCT06132945Phase 1
• Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney CancerActive, not recruitingNCT05239533Phase 2
• A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT03635892Phase 2
• Clinical and Histopathologic Characteristics of BAP1 MutationsCompletedNCT01773655
• A Study of RAD001 and Sunitinib in Metastatic Renal Cell CarcinomaCompletedNCT00422344Phase 1
• A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma PatientsCompletedNCT00421512Phase 1
• Vaccine Therapy in Treating Patients With Kidney CancerCompletedNCT00096629Phase 1
• Lenalidomide in Treating Patients With Advanced or Unresectable Kidney CancerCompletedNCT00096525Phase 2
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney CancerCompletedNCT00093405Phase 2
• Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney CancerCompletedNCT00045370Phase 1
• PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney CancerCompletedNCT00045279Phase 2
• PS-341 in Treating Patients With Metastatic Kidney CancerCompletedNCT00017329Phase 2
• ZD 1839 in Treating Patients With Metastatic Kidney CancerCompletedNCT00012337Phase 2
• Arsenic Trioxide in Treating Patients With Metastatic Kidney CancerCompletedNCT00005069Phase 2
• Interferon Alfa in Treating Patients With Advanced Kidney CancerCompletedNCT00003542Phase 1/2
• 6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney CancerCompletedNCT00003390Phase 2